Back to results
US 2022/0090085 A1Published application
Compositions and methods for reactivating latent immunodeficiency virus
AssigneeThe J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David Glads
InventorsMelanie Ott, Daniela Boehm
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus and/or reducing transcription of HIV integrated into the genome of an HIV-infected cell. The present disclosure provides compositions and methods for treating an immunodeficiency virus infection.
Claims12
(canceled)
A drug delivery device comprising:
- a) a first container comprising a SMYD2 inhibitor that reactivates latent immunodeficiency virus transcription;
- and
- b) a second container comprising an agent that inhibits an immunodeficiency virus function selected from viral replication, viral protease activity, viral reverse transcriptase activity, viral entry into a cell, viral integrase activity, viral Rev activity, viral Tat activity, viral Nef activity, viral Vpr activity, viral Vpu activity, and viral Vif activity.
Dependencies are inferred from the claim text.